speaker-icon

Latest Posts

anavex_partex_partnership_Innoplexus

27

Jun 23

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing

featured
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to...
Read More
Kittu-Press-Release

9

Feb 23

AI supports targeted therapy recommendations fortumor diseases – BMBF funds joint research projectat University Medical Center Mainz with 2.53 millionEuros

featured
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
Innoplexus-Innovatrix-partnership

Innoplexus and Innovatrix capital partner to bring about new risk-transfer solutions for the life science industry

Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning (ML) to bring about new risk-transfer solutions for the life science industry.

Eschborn, Germany/London, U.K., 27 July 2022
Innoplexus AG is pleased to announce that an agreement for a strategic partnership with Innovatrix Capital Ltd. has been concluded.

This exciting partnership has been struck to mutually enhance, grow and prosper within this novel business model brought forward by Innovatrix utilizing Innoplexus’ proprietary technology through its predictive clinical trial analysis engine. This engine is primarily based upon Innoplexus’ algorithms, AI and ML technology to generate a Probability of Success (PoS), which underpins Innovatrix’ suite of solutions.

Successful phase transition for clinical trials is crucial for the progression and development of new Life Science technologies with go-to-market possibilities depending on the positive outcomes of trials. This partnership will enhance the value-chain by combining Innoplexus’ deep-tech insight with risk-transfer solutions designed by Innovatrix, enabling growth for all stakeholders across Life Science research.

Innoplexus founder and CEO, Dr. Gunjan Bhardwaj points out that “Innoplexus is delighted to have entered this partnership with Innovatrix. Innoplexus being an AI leader at the forefront of technological innovation continues to strive for paradigm shifts in the entire sector.”

Innovatrix Co-founders, Qasim Akbar and Piers Clark, said “Innovatrix is very pleased to have partnered with Innoplexus who will be its exclusive provider of data and predictive analytics for the innovative Innovatrix Parametric Insurance proposition. The quality of Innoplexus’ analytics ​and AI services will be key element​s of Innovatrix’ groundbreaking product offering to the Life Science sector designed to ​mitigate the risk of investment in clinical trials and thereby facilitate and encourage investment in the sector.”

About Innoplexus AG

Innoplexus is a leading global AI-based company for drug discovery and development with over 300 employees and 125+ patent applications including 60+ grants in artificial intelligence, machine learning and blockchain technologies. Innoplexus’ solutions can generate real-time insights from hundreds of terabytes of structured and unstructured private and public data, thereby facilitating continuous, informed decision-making for its customer base at an unparalleled speed. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany, with offices in Pune, India, and Iselin and San Francisco, United States. For more info, please visit www.innoplexus.com

For further information contact:
Innoplexus AG
Claudia M. Hausoel, Chief Marketing Officer
E: claudia.hausoel@innoplexus.com
T: +49 (0) 151 – 6898 7478

About Innovatrix Capital Ltd.

Innovatrix is a Next-Gen Insurtech disrupter deploying cutting edge solutions for intangible risk transfer in the life sciences sector with a mission to encourage and facilitate investment in Research and Development.

Bringing together Parametric Insurance, capital markets and deep learning data science, Innovatrix’ product provides first of its kind protection against the risk of failure of clinical trials. For more information, please visit: www.innovatrixcap.co.uk

For further information contact:
Innovatrix Capital Ltd.

Piers Clark, Co-Founder and Director
E: piers@innovatrixcap.co.uk
T: +44 (0) 7714 457 450

Qasim Akbar, Co-Founder and Director
E: qasim@innovatrixcap.co.uk
T: +44 (0) 7896 734 905

Featured News

new_app_cancer_patients
on April 6, 2022

New app for cancer patients

Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…

Read More